Johnson & Johnson Discontinues CD20 and CD19-CD20 CAR-T Programs for Large B-Cell Lymphoma

Johnson & Johnson's exit from two CAR-T programs in large B-cell lymphoma signals the kind of portfolio rationalization that will reshape CDMO capacity planning and cell therapy manufacturing commitments across the sector. The company confirmed discontinuation of its investigational CD20 monospecific and CD19-CD20 bispecific CAR-T programs for LBCL, attributing the decision to portfolio prioritization and a shifting treatment landscape rather than any safety or efficacy signal.

For plant heads and QA directors managing dedicated cell therapy suites, the decision carries a direct operational read: manufacturing slots, validated processes, and qualified personnel aligned to these programs now require reallocation. CDMOs with capacity built around autologous CAR-T production will need to reassess utilization assumptions, particularly where process validation packages were scoped to J&J's specific vector and manufacturing platform requirements under 21 CFR Part 211 and applicable GMP frameworks.

Patients currently enrolled in ongoing trials will continue to receive support per study protocols, which means existing batch release obligations and chain-of-identity controls remain active in the near term. Regulatory affairs leads should confirm whether any open INDs tied to these programs require formal withdrawal notifications or protocol amendments with the FDA, as discontinuation outside of a safety-driven hold carries its own documentation obligations.

The broader CGT pipeline context adds weight to the decision. Elsewhere in the sector, mivocabtagene autoleucel (miv-cel; KYV-101), a fully human anti-CD19 CAR-T therapy developed by Kyverna Therapeutics, is advancing through the phase 2 KYSA-6 trial (NCT06193889) in myasthenia gravis, illustrating the pivot toward autoimmune indications that is drawing CAR-T investment away from crowded oncology spaces. Apertura Gene Therapy and the TSC Alliance also announced a preclinical collaboration using Apertura's TfR1 CapX AAV capsid platform for intravenous delivery in tuberous sclerosis complex, a program that will stress-test blood-brain barrier crossing efficiency at the bench before any GMP manufacturing scale-up is warranted.

For capacity planners, the measurable checkpoint is whether J&J's CDMO partners formally notify affected sites of program closure timelines and initiate technology transfer wind-down procedures consistent with ICH Q10 lifecycle management principles.

Source: CGTLive® via cgtlive.com, May 6, 2026.